This page contains a Flash digital edition of a book.
Healthcare products
for today and tomorrow
TECHNOLOGY
Interview with Peter Boonen, Managing Director, Stirling Products Limited.
BIO
Q:
What exactly does your company do?
increasing resistance to disease, reducing mortality
Peter BOONeN: Stirling Products is rates and providing for natural growth promotion.
a healthcare company headquartered in Sydney,
w
Australia with its operational base being in Charlotte- Short-Medium term – (6-18 months):
town, Canada. The Company has during the course of l Diabetin – is a natural botanical product that may prove
2009 joint ventures and licensed unique commercial- beneficial for the natural reduction of blood sugar.
ready products and medical device technologies to l Cholonorm – is a natural botanical product that may
supplement its existing products. The immediate and key prove beneficial for the natural reduction of LDL (bad)
focus of our consolidated operations is: cholesterol.
l Revenue generation: l Allergon – is a natural botanical product that may
– The global commercialisation of our joint ventured prove beneficial for a variety of allergies.
range of 26 botanical products; and l Completion of pre-production High Density Aerosol
– The commercialisation of our patented natural devices.
animal health product ProVale.
l Development: Longer term – (1-5 years):
– The continued development of our patented l Market release of the full range of botanical products.
animal growth promotion agent ST810 through l Subject to FDA approval and/or regulatory
our joint venture with Animate Animal Health base compliance, the gradual and phased release of off-
intervie
based in Johannesburg, South Africa; patent drugs for use through Stirling Products High
– The development of ST810 as a lead candidate Density Aerosol inhalation devices.
for obesity in humans (and animals); and l Market launch of ST810 as an animal growth
– The establishment of our High Density Aerosol promotion agent.
inhalation technology as a drug delivery platform. l Partnering with a major of the development of ST810
as a human obesity drug.
Q:
What are your key products?
BOONeN: Stirling’s key products and
commercialisation timelines are::
Q:
Your products are botanical based
rather than pharmaceutical – why
have you headed down the natural route?
Immediate: BOONeN: Essentially we are what we eat and good
l ImmunoXel – is a natural botanical balanced nutrition is the key to health. The benefits of
immunomodulator that in numerous clinical trials many fruits, vegetables, herbs and other plants are well
has proven to effective in the treatment of all forms established and also form a rapidly growing science field.
of TB as well as AIDS co-infection. We are focused Stirling’s botanical products have been developed and
on this aspect of commercialisation of ImmunoXel proven over a period of approximately 25 years. Extensive
particularly in Africa and South Africa. Also as clinical trials have been conducted during this time to
ImmunoXel has been shown to “fine tune” the support and also improve their efficacy. A good example is
human immune system, we are of the firm belief the efficacy of ImmunoXel in the treatment of all forms of TB
that as a dietary supplement, ImmunoXel could be and HIV co-infection. ImmunoXel is the only product in the
highly beneficial in assuring a healthy and robust past 40 years that has demonstrated any real difference in
immune system which scientists agree is the best the outcome of treated TB and TB/HIV patients.
possible natural defence to influenzas and possibly Although we do have a short to medium term focus
the current swine flu strain. (In Eastern Europe on our botanical products we do have the patents to
ImmunoXel has sold extensively for over 15 years as the world’s only single enantiomer beta agonist, a true
a cold and influenza preventative product). pharmaceutical, for the use in animal growth promotion
l ProVale – is a patented natural enhanced yeast and human and animal obesity. As Stirling Products is a
derivative that has been proven to improve the health small company that is very aware of the challenges and
of meat production animals and aquaculture in costs involved in the development of pharmaceutical
84 INVEST IN AUSTRALIA – INDIA
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108
Produced with Yudu - www.yudu.com